RECORMON

This brand name is authorized in Brazil, Ecuador, Hong Kong SAR China, Israel, Singapore.

Active ingredients

The drug RECORMON contains one active pharmaceutical ingredient (API):

1	Epoetin beta UNII 64FS3BFH5W - EPOETIN
	Epoetin beta stimulates erythropoiesis by interaction with the erythropoietin receptor on progenitor cells in the bone marrow. Epoetin beta is a continuous erythropoietin receptor activator that shows a different activity at the receptor level characterized by a slower association to and faster dissociation from the receptor, a reduced specific activity in vitro with an increased activity in vivo, as well as an increased half-life, in contrast to erythropoietin.
	Read more about Epoetin beta

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B03XA01	Erythropoietin	B Blood and blood forming organs → B03 Antianemic preparations → B03X Other antianemic preparations → B03XA Other antianemic preparations
Discover more medicines within B03XA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	529204402158212
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	24.129-1-07-11, 24.155-1-07-11, 26.049-11-04
HK	Department of Health Drug Office	47137, 47139, 49039, 58012, 59379, 59381
IL	מִשְׂרַד הַבְּרִיאוּת	4180, 4182, 6555, 6557, 8487
SG	Health Sciences Authority	11418P, 11423P, 11501P, 13041P